In the following studies (all including patients with type 2 diabetes and micro- or macroalbuminuria), heart failure was more common than other cardiovascular complications: reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) [21], the Irbesartan Diabetic Nephropathy Trial (IDNT) [22], the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE) [23] and Microvascular outcomes in the Heart Outcomes Prevention Evaluation Study (MICRO-HOPE) [24]. The gene discussed is AGT; the disease is diabetic kidney disease.